← Latest news 
India pharma exports hit compliance squeeze forcing a new quality led playbook
India
Published on 30 April 2026
New scrutiny is reshaping who can export and how
As global regulators tighten standards, India’s pharma industry is moving beyond its old cost advantage toward tighter compliance, quality systems, and regulatory trust. With scrutiny rising across target markets, exporters face higher expectations on documentation, testing, and manufacturing practices, pushing the $30 billion export engine to recalibrate its playbook for long term access.
- Global buyers are prioritizing regulatory trust over just low costs
- India’s exporters are upgrading compliance and quality systems
- Rising scrutiny is increasing the cost and complexity of exporting
- Long term market access will depend on meeting stricter standards
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times